Products for Research Use Only

Ionomycin

CAT: 0804-HY-13434-02Size: 5 mg (14.1 mM x 500 μL in Ethanol)Dry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13434-02Size:5 mg (14.1 mM x 500 μL in Ethanol)
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ionomycin (SQ23377) is a potent, selective calcium ionophore and an antibiotic produced by Streptomyces conglobatus. Ionomycin (SQ23377) is highly specific for divalent cations (Ca>Mg>Sr=Ba) . Ionomycin (SQ23377) promotes apoptosis. Ionomycin also induces the activation of protein kinase C (PKC) [1][2][3].
CAS Number
56092-81-0
Product Name Alternative
SQ23377
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Apoptosis; Bacterial; Calcium Channel; PKC
Type
Natural Products
Related Pathways
Anti-infection; Apoptosis; Epigenetics; Membrane Transporter/Ion Channel; Neuronal Signaling; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/Ionomycin.html
Concentration
14.1 mM * 5 mL in Ethanol
Purity
99.27
Smiles
O=C(O)CC[C@@H](C)C[C@H](C)C[C@H](C)C(/C=C(O)/[C@H](C)C[C@H](C)C/C=C/[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](O)C[C@@H]1CC[C@]([C@@H]2O[C@](C)([C@H](O)C)CC2)(C)O1)=O
Molecular Formula
C41H72O9
Molecular Weight
709.01
Precautions
H302, H315, H319, H335
References & Citations
[1]Liu C, et al. Characterization of ionomycin as a calcium ionophore. J Biol Chem. 1978 Sep 10;253 (17) :5892-4.|[2]Chatila T, et al. Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol. 1989 Aug 15;143 (4) :1283-9.|[3]Gil-Parrado S, et al. Ionomycin-activated calpain triggers apoptosis. A probable role for Bcl-2 family members. J Biol Chem. 2002 Jul 26;277 (30) :27217-26.|[4]Stoeck A, et al A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J. 2006 Feb 1;393 (Pt 3) :609-18.|[5]Junsuke Uwada, et al. Store-operated calcium entry (SOCE) contributes to phosphorylation of p38 MAPK and suppression of TNF-α signalling in the intestinal epithelial cells. Cell Signal. 2019 Nov;63:109358.
Shipping Conditions
Blue Ice
Storage Conditions
Solution, -20°C, 2 years
Scientific Category
Natural Products
Clinical Information
No Development Reported
Citation 01
ACS Infect Dis. 2023 Apr 14;9 (4) :979-992.|Acta Pharm Sin B. 2024 Oct;14 (10) :4360-4377.|Acta Pharmacol Sin. 2023 Apr;44 (4) :811-821.|Adv Funct Mater. 2025 May 22.|Adv Sci (Weinh) . 2023 Mar;10 (7) :e2203869.|Adv Sci (Weinh) . 2024 Jul;11 (26) :e2400297.|Adv Sci (Weinh) . 2024 May;11 (19) :e2306378.|Adv Sci (Weinh) . 2025 Jun 19:e00225.|Adv Sci (Weinh) . 2025 Sep 15:e10102.|Aging (Albany NY) . 2021 Mar 24;13 (7) :10312-10325.|Aging. 2019 Aug 19;11 (16) :6490-6502.|Aging. 2021 Jun 2;13 (11) :15638-15658.|Arch Oral Biol. 2024 Jul 3:166:106043.|Biochem Pharmacol. 2024 Jan:219:115957.|Biochem Pharmacol. 2025 Dec;242 (Pt 3) :117406.|Biomed Pharmacother. 2022 Mar:147:112644.|Biomed Pharmacother. 2024 May:174:116551.|BMC Med. 2023 Dec 20;21 (1) :507.|BMC Med. 2025 Mar 31;23 (1) :189.|Cancer Cell. 2023 Jun 12;41 (6) :1170-1185.e12.|Cancer Commun (Lond) . 2022 Jan;42 (1) :17-36.|Cancer Immunol Res. 2025 Jul 2;13 (7) :1037-1052.|Cancer Res. 2023 Mar 15;83 (6) :906-921.|Cell Calcium. 2022 Jun;104:102571.|Cell Death Differ. 2025 Apr 16.|Cell Death Dis. 2021 Apr 1;12 (4) :336.|Cell Death Dis. 2025 Apr 15;16 (1) :301.|Cell Metab. 2024 Jun 18:S1550-4131 (24) 00189-X.|Cell Mol Immunol. 2022 Apr;19 (4) :540-553.|Cell Mol Life Sci. 2025 May 28;82 (1) :218.|Cell Rep. 2021 Jul 20;36 (3) :109404.|Cell Rep. 2024 Mar 23;43 (4) :114003.|Cell Rep. 2025 Jun 12;44 (6) :115857.|Cell Rep. 2025 Jun 13;44 (6) :115851.|Cell Rep. 2025 Sep 1;44 (9) :116139.|Cell Res. 2025 Feb;35 (2) :97-116.|Cell Stem Cell. 2025 May 1;32 (5) :778-794.e10.|Cell. 2025 Dec 11;188 (25) :7291-7308.e23.|Cytotechnology. 2024 Apr 24:1-8.|EBioMedicine. 2024 Aug 6:106:105269.|Ecotoxicol Environ Saf. 2024 Jan 15:270:115831.|EMBO Rep. 2025 Nov 17.|Eur J Med Res. 2025 May 12;30 (1) :378.|Eur J Pharmacol. 2022 Feb 5:916:174623.|Evid Based Complement Alternat Med. 2021 Jan 6:2021:8868527.|Fish Shellfish Immunol. 2024 May:148:109515.|Fish Shellfish Immunol. 2024 Nov:154:109975.|Front Immunol. 2022 Aug 5:13:918241.|Gut Microbes. 2024 Jan-Dec;16 (1) :2410474.|Hum Reprod. 2024 Apr 3;39 (4) :658-673.|Int Immunopharmacol. 2023 Sep 1;124 (Pt A) :110865.|Int Immunopharmacol. 2024 Sep 16;142 (Pt B) :113170.|Int Immunopharmacol. 2025 May 20:159:114897.|Int Immunopharmacol. 2026 Jan 1;168 (Pt 1) :115803.|Int J Biol Macromol. 2023 Jul 31:244:125373.|Int J Mol Sci. 2023 Aug 8;24 (16) :12557.|Int J Mol Sci. 2025 Jun 1;26 (11) :5332.|Int J Mol Sci. 2025 May 20;26 (10) :4913.|iScience. 2025 May 13;28 (7) :112658.|J Cell Mol Med. 2024 Aug;28 (15) :e18589.|J Cell Mol Med. 2025 Feb;29 (3) :e70403.|J Cell Mol Med. 2025 Oct;29 (20) :e70915.|J Clin Invest. 2025 Aug 1;135 (15) :e191119.|J Ethnopharmacol. 2023 Mar 1:303:116031.|J Immunol. 2021 Mar 1;206 (5) :963-977.|J Immunother Cancer. 2024 Dec 9;12 (12) :e009910.|J Immunother Cancer. 2025 Jul 31;13 (7) :e012029.|J Nanobiotechnology. 2024 Sep 12;22 (1) :556.|J Neuroimmunol. 2020 Aug 15;345:577286.|J Periodontol. 2025 Apr;96 (4) :355-368.|J Transl Med. 2024 Dec 20;22 (1) :1125.|J Transl Med. 2025 Nov 14;23 (1) :1289.|Microorganisms. 2023 Feb 27;11 (3) :604.|Mol Cell. 2022 Jul 7;82 (13) :2401-2414.e9.|Mol Med. 2024 Jul 30;30 (1) :110.|Nat Cancer. 2025 May;6 (5) :768-785.|Nat Commun. 2023 Feb 23;14 (1) :1020.|Nat Commun. 2025 Mar 19;16 (1) :2728.|Nat Commun. 2025 Nov 24;16 (1) :10384.|Oncol Rep. 2024 Feb;51 (2) :29.|Phytomedicine. 2025 Jun 20:145:157017.|PLoS Pathog. 2025 Feb 4;21 (2) :e1012912.|PLoS Pathog. 2025 Nov 14;21 (11) :e1013686.|Preprints. 2023 Mar 6.|Preprints. 2025 Feb 12.|Proc Natl Acad Sci U S A. 2022 Feb 22;119 (8) :e2114851119.|Protein Cell. 2022 Apr;13 (4) :281-301.|Redox Biol. 2023 Dec:68:102959.|Reprod Fert Develop. 33 (2) 108-108.|Research Square Preprint. 2023 Aug 11.|Research Square Print. 2022 Jun.|Sci Signal. 2023 Feb 28;16 (774) :eadd0645.|Sci Total Environ. 2021 Jul 20:779:146523.|Sci Transl Med. 2020 Nov 25;12 (571) :eaaz6667.|SSRN. 2025 Jul 24.|Theranostics. 2023 May 8;13 (9) :2879-2895.|Theranostics. 2025 May 25;15 (13) :6329-6346.|Vaccines. 2023 May 25;11 (6) :1026.|Vet Microbiol. 2025 Apr 23:305:110529.|Virulence. 2025 Oct 28:2580150.|Cell Host Microbe. 2025 Jun 11;33 (6) :915-931.e9.|Immunobiology. 2024 Nov;229 (6) :152854.|Int Immunopharmacol. 2024 Jan 5:126:111212.|J Cell Sci. 2025 Nov 17:jcs.264186.|OncoImmunology. 2023 Oct 12;12 (1) :2268257.

Chemical Information

Ionomycin

Ionomycin is a very long-chain fatty acid that is docosa-10,16-dienoic acid which is substituted by methyl groups at positions 4, 6, 8, 12, 14, 18 and 20, by hydroxy groups at positions 11, 19 and 21, and by a (2',5-dimethyloctahydro-2,2'-bifuran-5-yl)ethanol group at position 21. An ionophore produced by Streptomyces conglobatus, it is used in research to raise the intracellular level of Ca2+ and as a research tool to understand Ca2+ transport across biological membranes. It has a role as a calcium ionophore and a metabolite. It is a polyunsaturated fatty acid, a very long-chain fatty acid, an enol and a cyclic ether.

CAS Number56092-81-0
PubChem CID6912226
IUPAC Name(4R,6S,8S,10Z,12R,14R,16E,18R,19R,20S,21S)-11,19,21-trihydroxy-22-[(2S,5S)-5-[(2R,5S)-5-[(1R)-1-hydroxyethyl]-5-methyloxolan-2-yl]-5-methyloxolan-2-yl]-4,6,8,12,14,18,20-heptamethyl-9-oxodocosa-10,16-dienoic acid
Molecular FormulaC41H72O9
Molecular Weight709.0
XLogP7.5
Topological Polar Surface Area154
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count9
Rotatable Bond Count22
Heavy Atom Count50
Formal Charge0
Complexity1120
SMILES
C[C@H](CCC(=O)O)C[C@H](C)C[C@H](C)C(=O)/C=C(/[C@H](C)C[C@H](C)C/C=C/[C@@H](C)[C@H]([C@@H](C)[C@H](C[C@@H]1CC[C@@](O1)(C)[C@H]2CC[C@@](O2)(C)[C@@H](C)O)O)O)\O
InChI
InChI=1S/C41H72O9/c1-25(21-29(5)34(43)24-35(44)30(6)22-27(3)20-26(2)14-15-38(46)47)12-11-13-28(4)39(48)31(7)36(45)23-33-16-18-41(10,49-33)37-17-19-40(9,50-37)32(8)42/h11,13,24-33,36-37,39,42-43,45,48H,12,14-23H2,1-10H3,(H,46,47)/b13-11+,34-24-/t25-,26-,27+,28-,29-,30+,31+,32-,33+,36+,37-,39-,40+,41+/m1/s1
InChIKey
PGHMRUGBZOYCAA-ADZNBVRBSA-N
Chemical Structure
2D Structure
2D structure of Ionomycin
CAS: 56092-81-0
CID: 6912226
Formula: C41H72O9
MW: 709.0
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight709.0
XLogP37.5
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count9
Rotatable Bond Count22
Exact Mass708.51763387
Monoisotopic Mass708.51763387
Topological Polar Surface Area154 Ų
Heavy Atom Count50
Formal Charge0
Complexity1120
Isotope Atom Count0
Defined Atom Stereocenter Count14
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count2
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes